CAJ | 학술논문

目的：探讨使用恩替卡韦辅助治疗慢性乙型肝炎的近期疗效。方法以我院2013－04～2014－04间收治的慢性乙型肝炎患者140例为研究对象，将其随机分为观察组与对照组。对照组口服阿德福韦酯，观察组在此基础上增加服用恩替卡韦，比较两组患者临床效果。结果观察组患者在治疗后6周、治疗后12周及治疗后24周时，乙肝病毒脱氧核糖核酸（ HBV DNA）载量显著低于对照组（P＜0．05）。而转化生长因子β1（TGF－β1）水平的比较中，则未见显著差异（P＞0．05）。结论恩替卡韦可以作为一种辅助用药，有效作用于慢性乙型肝炎患者抗病毒治疗。
목적：탐토사용은체잡위보조치료만성을형간염적근기료효。방법이아원2013－04～2014－04간수치적만성을형간염환자140례위연구대상，장기수궤분위관찰조여대조조。대조조구복아덕복위지，관찰조재차기출상증가복용은체잡위，비교량조환자림상효과。결과관찰조환자재치료후6주、치료후12주급치료후24주시，을간병독탈양핵당핵산（ HBV DNA）재량현저저우대조조（P＜0．05）。이전화생장인자β1（TGF－β1）수평적비교중，칙미견현저차이（P＞0．05）。결론은체잡위가이작위일충보조용약，유효작용우만성을형간염환자항병독치료。
Objective To study the clinical effects of 24 weeks entecavir antiviral therapy on chronic hepatitis B.Methods A total of 140 patients, received from April 2013 to April 2014, with chronic hepatitis B were included in this study and randomly divided into study group and control group.Patients in control group were treated by adefovir dipivoxil and patients in study group were treated by entecavir ad-ditionally.The clinical effects were compared between two groups.Results The HBV DNA load in study group was significantly lower than that in control group, at 6 weeks, 12 weeks and 24 weeks after treatment.There was no significant difference of serum TGF-β1 between two groups(P>0.05).Conclusion Entecavir is a effective adjuvant drug in chronic hepatitis B antiviral therapy.